On Thursday, Shares of General Electric Company (NYSE:GE), gained 4.16% to $25.01.
Academic medical centers across the U.S. are experiencing increasing pressure to enhance value – deliver higher quality at lower cost – as they continue to face challenges related to outcomes, cost control, market competition, and other dynamics. Initiatives to promote value typically involve reimbursement arrangements between health insurers and providers that align financial, efficiency and quality incentives.
Recently, Temple University Health System (TUHS) and GE Healthcare declared a pioneering, first-of-its-kind risk partnership between a health care technology company and an academic medical center that aligns incentives to promote value by providing higher-quality radiologic imaging services more efficiently at a lower cost.
The new arrangement targets improvements in specific operational, clinical and financial outcomes, putting TUHS on the cutting edge of delivering high-value imaging services across a health system and making GE Healthcare a pioneer in what could become a preferred business model over the next few years.
Under the seven-year agreement, TUHS and GE Healthcare will work together to achieve performance aims enabled by new technology and industry best practices. TUHS will modernize its radiological imaging equipment with state-of-the art technology from GE, while also benefitting from enhancements, counting data storage and retrieval, service contract consolidation and consultation to optimize scheduling and workflow efficiency. The arrangement comprises financial incentives aligning the parties toward realizing shared objectives, counting a targeted $39 million in operational savings over the life of the contract.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment.
Shares of Kinder Morgan, Inc. (NYSE:KMI), inclined 3.93% to $32, during its last trading session, as oil soared more than 10 percent Thursday, its biggest one-day gain since March 2009, lifted by resurgent global stock markets and a report showing the U.S. economy grew faster than formerly stated in the second quarter.
U.S. oil rose $3.96, or 10.3 percent, to $42.56 in New York. That is the biggest gain since March 12, 2009, when oil gained 11 percent. Brent crude rose 10.3 percent to $47.56 a barrel in London.
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments.
Finally, OvaScience, Inc. (NASDAQ:OVAS), ended its last trade with 2.64% gain, and closed at $21.38.
OvaScience declared the first published analysis of real-world patient experience comparing the AUGMENTSM fertility treatment to standard in vitro fertilization (IVF). In the same woman within the same IVF cycle, AUGMENT-treated eggs had statistically noteworthy higher rates of embryo selection and transfer based on standard embryo quality measures, which resulted in statistically noteworthy higher rates of pregnancy, contrast to standard IVF.
The report, published recently in the peer-reviewed, Journal of Fertilization: In Vitro– IVF-Worldwide Reproductive Medicine, Genetic & Stem Cell Biology, comprises a formerly described subset of 25 patients at Fakih IVF in the United Arab Emirates (UAE) whose eggs were prospectively allocated to two treatment groups – one that received the AUGMENT treatment and the other that received standard IVF only. The publication also comprises the combined experience of more than 90 patients from Fakih IVF and TCART Fertility Partners in Canada that showed substantial improvements in pregnancy rates with the AUGMENT treatment contrast to the patients’ preceding IVF histories.
“This first publication of AUGMENT experience from different IVF clinics shows that AUGMENT treatment resulted in higher ongoing clinical pregnancy rates and healthy births when contrast to standard IVF,” said Robert F. Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners. “In addition, the new analysis by Fakih IVF demonstrated statistically noteworthy higher rates of embryo selection and transfer with the AUGMENT treatment. This provides further evidence that the AUGMENT treatment has the potential to improve egg health and embryo quality, and may offer a new treatment option to improve IVF success.”
OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
